OBJECTIVES: Current cost studies describing people with epilepsy do not segment the populations by seizure type.  This paper produces an economic model of people experiencing seizures, including individuals with epilepsy, broken into novel categories useful in assessing the potential effect of future interventions. METHODS: Three-year’s worth of administrative claims data from Milliman’s commercially-insured research dataset (n=16.8 million 2012) was grouped into benefit service cost categories.   Individuals experiencing seizures were extracted whose coverage included prescription drugs and whose medical claims contained the following ICD9CM diagnosis codes:  345.00, 345.01, 345.10, 345.11, 345.2, 345.3, 345.40, 345.41, 345.50, 345.51 and 780.33.  Individuals were grouped into three novel categories:  Motor Seizures (345.10, 345.11, 345.3, 345.40, and 345.41), Post Traumatic Seizures (780.33) and Non-Motor Seizures (345.00, 345.01, 345.2, 345.50, and 345.51).   RESULTS: Individuals experiencing seizures represented 0.4% of the population and accounted for 1.8% of allowed claims dollars.  The odds of being admitted to the hospital for the Motor and Non-Motor Seizure groups were 5.5 and 4 times higher, respectively, with a 2-day longer average length of stay and total allowed claims dollars were 5 and 4.2 times higher, respectively, than the standard population. The odds of being admitted for the Post Traumatic group was 9 times higher with an average length of stay almost 4 days longer and total allowed claims dollars were 6 times higher than the standard population.  Other cost and utilization measures produced similar results.  CONCLUSIONS: Individuals experiencing seizures are expensive when compared to the standard population. The excess utilization is in manageable healthcare cost categories.  By utilizing these novel groups, case managers may find new ways to manage patients with epilepsy, target interventions and measure the success of those interventions.